Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jean-Marie Canan Insider Profile
4 Followers
Jean-Marie Canan, Director at Acasti Pharma, holds 117.50K shares in Acasti Pharma (Ticker: ACST). Most recently, Jean-Marie Canan Bought $10,000 shares of Acasti Pharma on Aug 21, 2019 for an estimated value of 18.89K.
Profitable Transactions
1 out of 4 Profitable Transactions
Average Return
-1.80%
Average return per transaction
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Jean-Marie Canan's holdings
Insider Roles
Director
Roles that Jean-Marie Canan holds in companies
Most Profitable Insider Trade
The most profitable trade made by Jean-Marie Canan
Jean-Marie Canan's Trading History
List of latest transactions for each holding click on a transaction to see Jean-Marie Canan's performance on stock
You May Also Like
Jean-Marie Canan insider profile FAQ
What is the percentage of profitable transactions made by Jean-Marie Canan?
The percentage of profitable transactions made by Jean-Marie Canan is 25%.
What is the average return per transaction made by Jean-Marie Canan?
The average return per transaction made by Jean-Marie Canan is -1.80%.
What stocks does Jean-Marie Canan hold?
Jean-Marie Canan holds: ACST stocks.
What was Jean-Marie Canan’s latest transaction?
Jean-Marie Canan latest transaction was an Informative Buy of $18.89K.
What was Jean-Marie Canan's most profitable transaction?
Jean-Marie Canan’s most profitable transaction was an Informative Buy of ACST stock on October 24, 2018. The return on the trade was 84.30%.
What is Jean-Marie Canan's role in Acasti Pharma?
Jean-Marie Canan's role in Acasti Pharma is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.